Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Facing the Reality of Drug-Resistant Tuberculosis in India: Challenges and Potential Solutions

Free Books & Documents
Review

Facing the Reality of Drug-Resistant Tuberculosis in India: Challenges and Potential Solutions

Institute of Medicine (US).
Free Books & Documents

Excerpt

Presentations at the workshop addressed the following topics: TB (tuberculosis) and MDR (multi-drug resistant) TB in India, including local and national responses to the epidemic (Chapter 2); the global burden of TB and drug-resistant TB, including data from another high-burden country, China (Chapter 3); prevention of the transmission of drug-resistant TB in India (Chapter 4); rapid methods of detecting drug resistance and strengthening laboratory capacity (Chapter 5); approaches to reaching vulnerable populations affected by drug-resistant TB (Chapter 6); public–private engagement and innovative methods in combating drug-resistant TB (Chapter 7); the drug supply chain for second-line drugs (Chapter 8); and the major viewpoints expressed at the workshop and next steps suggested by workshop participants (Chapter 9).

PubMed Disclaimer

Grants and funding

This study was supported by contracts between the National Academy of Sciences and Department of Health and Human Services (Contract Nos. N01-OD-4-2139 and 223001003T), U.S. State Department (S-LMAQM-08-GR-071), American Society for Microbiology, Amgen Inc., Association of American Medical Colleges, Bristol-Myers Squibb, Burroughs Wellcome Fund, Celtic Therapeutics, LLLP, Critical Path Institute, Doris Duke Charitable Foundation, Eli Lilly & Co., FasterCures, Foundation for the NIH, Friends of Cancer Research, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc.

LinkOut - more resources